

Bayer plans cooperation agreement with Boehringer Ingelheim

Pharmaceuticals Division signs declaration of intent to market telmisartan

Innovative drug for the treatment of high blood pressure

Leverkusen – Bayer AG's Pharmaceuticals Division and Boehringer Ingelheim, Ingelheim, Germany, have signed a letter of intent concerning the marketing of telmisartan. The agreement also covers a recently approved combination product containing telmisartan and a diuretic.

The planned cooperation agreement will govern the co-marketing of the antihypertensive drug in Germany, Scandinavia and Switzerland. Bayer provisionally plans to launch the product in January 2003. The active ingredient telmisartan is protected by patent until 2012.

"This product suits our European portfolio of cardiovascular drugs extremely well. Furthermore, telmisartan will allow our field force to impressively demonstrate their expertise. The cooperation agreement is therefore an ideal, complementary fit for both companies," said Dr. Wolfgang Plischke, Head of the Pharmaceuticals Division of Bayer HealthCare, Bayer AG.

"Telmisartan has an excellent medical profile and a high priority for Boehringer Ingelheim. That is why we will exploit its full potential in all markets and territories by cooperating with strong partners. In addition to our co-promotion / co-marketing strategies with Abbott and GlaxoSmithKline in certain countries, we are happy to work with Bayer in Germany, Scandinavia and Switzerland," said Prof. Rolf Krebs, Chairman of the Board of Managing Directors of Boehringer Ingelheim.

Bayer and Boehringer will continue to look for opportunities to extend their

collaborative work on telmisartan to other countries.

Telmisartan is an angiotensin II antagonist, a class of drugs characterized by the strongest growth in the antihypertensives market.

Leverkusen, August 15, 2002

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F).The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.